Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus

Li, Jiaoran; Liu, Yanping; Hao, Panpan

doi:10.1016/j.diabres.2023.110798

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pharmacological and Non-pharmacological Treatments Of Hfpef1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DPP-4 inhibitors may reduce all-cause mortality in specific subgroups of HF patients, especially in women and those with HFpEF, while maintaining a favorable coronary safety profile. Additionally, the use of DPP-4 inhibitors was found to be associated with improved long-term outcomes in HFpEF patients with diabetes mellitus [ 49 , 50 ].…”

Section: Pharmacological and Non-pharmacological Treatments Of Hfpefmentioning

confidence: 99%

Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment

Wang,

Fu,

Wang

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Heart failure (HF) is a complex, life-threatening condition characterized by high mortality, morbidity, and poor quality of life. Despite studies of epidemiology, pathogenesis, and therapies, the rate of HF hospitalization is still increasing due to the growing and aging population and an increase in obesity in relatively younger individuals. It remains a predominant issue in the public health and the global economic burden. Current research has focused on how HF affects the entire range of left ventricular ejection fraction (LVEF), especially the three HF subgroups. This review provides a latest overview of pharmacological and non-pharmacological strategies of these three subgroups (HF with preserved ejection fraction, HF with reduced ejection fraction, and HF with mildly reduced ejection fraction). We summarize conventional therapies, investigate novel strategies, and explore the new technologies such as aortic thoracic stimulation and interatrial shunting devices.

show abstract

Section: Pharmacological and Non-pharmacological Treatments Of Hfpefmentioning

confidence: 99%